Nuformix (LON:NFX) Reaches New 1-Year Low – Here’s Why

Nuformix plc (LON:NFX – Get Free Report) shares hit a new 52-week low during mid-day trading on Thursday. The stock traded as low as GBX 0.12 and last traded at GBX 0.12, with a volume of 52582754 shares trading hands. The stock had previously closed at GBX 0.14.

Nuformix Trading Down 11.1%

The stock has a market cap of £3.13 million, a PE ratio of -4.10 and a beta of 1.53. The business has a 50-day moving average price of GBX 0.15 and a 200 day moving average price of GBX 0.17.

About Nuformix

(Get Free Report)

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications.

Further Reading

Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.